Reuters logo
BRIEF-Kitov completes KIT-302 testing required for NDA to U.S. FDA
December 7, 2016 / 2:30 PM / a year ago

BRIEF-Kitov completes KIT-302 testing required for NDA to U.S. FDA

Dec 7 (Reuters) - Kitov Pharmaceuticals Holdings Ltd :

* Kitov Pharmaceuticals Holdings - Kitov expects to submit additional stability data to FDA at a later time, in order to extend labeled shelf life

* Kitov successfully completes all KIT-302 testing required for new drug application to U.S. FDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below